Back to top
more

Boundless Bio, Inc. (BOLD)

(Real Time Quote from BATS)

$3.62 USD

3.62
15,709

-0.08 (-2.16%)

Updated Nov 13, 2024 11:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Down -31.59% in 4 Weeks, Here's Why You Should You Buy the Dip in Boundless Bio, Inc. (BOLD)

by Zacks Equity Research

Boundless Bio, Inc. (BOLD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down

by Zacks Equity Research

AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.

Agenus Initiates Phase I Study on Oncology Candidate AGEN1223

by Zacks Equity Research

Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.

Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline

by Zacks Equity Research

Astellas (ALPMY) acquires Xyphos and gains the latter's novel and proprietary ACCEL technology platform.

Sarepta Signs Gene Therapy Agreement With Roche for $1.15B

by Zacks Equity Research

Sarepta (SRPT) grants ex-U.S. marketing rights of its gene therapy DMD candidate, SRP-9001, to Roche for an upfront payment of $1.15 billion. Sarepta is also eligible to receive $1.7 billion in milestone payments.

Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up

by Zacks Equity Research

Sarepta (SRPT) exon-53 skipping DMD drug, Vyondys 53, gets approval in the United States following a CRL in August.

Ekta Bagri headshot

4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal

by Ekta Bagri

Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.

Company News for Dec 4, 2019

by Zacks Equity Research

Companies In The News Are: UNH,PEP,CLF,AKS,BOLD.

Sarepta Stock Falls as FDA Denies Approval to Golodirsen

by Zacks Equity Research

The CRL to golodirsen NDA comes as a surprise for Sarepta (SRPT) and investors as no issues were raised by the FDA during the review period that could have lead to non-approval of the candidate.

    Solid Biosciences Surges on DMD Gene Therapy Study Amendments

    by Zacks Equity Research

    Solid Biosciences (SLDB) amends its phase I/II gene therapy study protocol to expedite the development of its lead candidate, SGT-001, as potential treatment for DMD.

    Indrajit Bandyopadhyay headshot

    4 Gene Therapy Players Likely to Become Buyout Targets in 2019

    by Indrajit Bandyopadhyay

    Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

    Audentes Therapeutics (BOLD) Upgraded to Buy: Here's What You Should Know

    by Zacks Equity Research

    Audentes Therapeutics (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Sweta Killa headshot

    Biotech ETFs Jump on Roche-Spark Deal

    by Sweta Killa

    The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

    Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%

    by Zacks Equity Research

    Audentes Therapeutics (BOLD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

    Is Audentes Therapeutics (BOLD) Stock Outpacing Its Medical Peers This Year?

    by Zacks Equity Research

    Is (BOLD) Outperforming Other Medical Stocks This Year?

      Ekta Bagri headshot

      3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018

      by Ekta Bagri

      Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.

        Is a Surprise Coming for Audentes Therapeutics (BOLD) This Earnings Season?

        by Zacks Equity Research

        Audentes Therapeutics (BOLD) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

          Audentes Therapeutics (BOLD) Jumps: Stock Rises 14.9%

          by Zacks Equity Research

          Audentes Therapeutics, Inc. (BOLD) was a big mover last session, as the company saw its shares nearly 15% on the day amid huge volumes.

            Why Audentes Therapeutics (BOLD) Could Be Positioned for a Surge

            by Zacks Equity Research

            Audentes Therapeutics (BOLD) is seeing positive earnings estimate revisions suggesting that it could be a solid choice for investors.